Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 68 | 2019 | 173 | 8.610 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 43 | 2018 | 401 | 3.360 |
Why?
|
Leukemia, Promyelocytic, Acute | 15 | 2018 | 21 | 2.900 |
Why?
|
Mutation | 26 | 2019 | 466 | 2.130 |
Why?
|
Antineoplastic Agents | 20 | 2018 | 546 | 1.500 |
Why?
|
MicroRNAs | 19 | 2017 | 173 | 1.330 |
Why?
|
Middle Aged | 100 | 2019 | 10805 | 1.280 |
Why?
|
Cytarabine | 25 | 2018 | 52 | 1.240 |
Why?
|
Aged | 81 | 2019 | 9462 | 1.180 |
Why?
|
Prognosis | 45 | 2019 | 1362 | 1.100 |
Why?
|
Oxides | 6 | 2014 | 14 | 1.050 |
Why?
|
Arsenicals | 6 | 2014 | 12 | 1.050 |
Why?
|
Female | 102 | 2019 | 18114 | 1.050 |
Why?
|
Treatment Outcome | 49 | 2018 | 3099 | 1.030 |
Why?
|
Male | 100 | 2019 | 17768 | 1.010 |
Why?
|
Adult | 75 | 2019 | 8391 | 1.010 |
Why?
|
Gene Expression Profiling | 22 | 2017 | 320 | 1.000 |
Why?
|
Humans | 123 | 2019 | 29013 | 0.970 |
Why?
|
Aged, 80 and over | 47 | 2019 | 3712 | 0.970 |
Why?
|
Disease-Free Survival | 32 | 2019 | 281 | 0.950 |
Why?
|
Young Adult | 34 | 2019 | 2398 | 0.930 |
Why?
|
Remission Induction | 27 | 2018 | 78 | 0.840 |
Why?
|
Leukemia, Myeloid | 12 | 2011 | 24 | 0.830 |
Why?
|
Geriatric Assessment | 3 | 2016 | 355 | 0.770 |
Why?
|
Gene Expression Regulation, Leukemic | 12 | 2014 | 23 | 0.760 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2013 | 39 | 0.740 |
Why?
|
Adolescent | 40 | 2019 | 3248 | 0.710 |
Why?
|
Daunorubicin | 18 | 2018 | 26 | 0.700 |
Why?
|
Sulfides | 2 | 2018 | 24 | 0.660 |
Why?
|
Caprylates | 2 | 2018 | 25 | 0.660 |
Why?
|
Chromosome Aberrations | 6 | 2019 | 21 | 0.660 |
Why?
|
fms-Like Tyrosine Kinase 3 | 11 | 2014 | 16 | 0.650 |
Why?
|
Survival Rate | 25 | 2019 | 795 | 0.640 |
Why?
|
Deglutition Disorders | 1 | 2016 | 50 | 0.560 |
Why?
|
Aorta, Thoracic | 1 | 2016 | 72 | 0.550 |
Why?
|
Neoplasm Proteins | 12 | 2017 | 141 | 0.550 |
Why?
|
Survival Analysis | 21 | 2016 | 440 | 0.540 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2011 | 12 | 0.520 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 28 | 0.500 |
Why?
|
Tretinoin | 7 | 2018 | 34 | 0.490 |
Why?
|
Myelodysplastic Syndromes | 6 | 2017 | 22 | 0.480 |
Why?
|
Community Networks | 1 | 2013 | 26 | 0.450 |
Why?
|
Resilience, Psychological | 1 | 2013 | 15 | 0.450 |
Why?
|
Developing Countries | 1 | 2013 | 43 | 0.450 |
Why?
|
Karyotyping | 13 | 2019 | 27 | 0.440 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2013 | 43 | 0.440 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2012 | 17 | 0.440 |
Why?
|
Drug Administration Schedule | 9 | 2018 | 246 | 0.430 |
Why?
|
Translocation, Genetic | 4 | 2017 | 17 | 0.430 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2018 | 89 | 0.390 |
Why?
|
Recurrence | 8 | 2018 | 235 | 0.390 |
Why?
|
Tumor Suppressor Proteins | 4 | 2018 | 72 | 0.370 |
Why?
|
Azacitidine | 4 | 2016 | 28 | 0.370 |
Why?
|
Immunotoxins | 3 | 2007 | 16 | 0.370 |
Why?
|
Neoplasm Staging | 6 | 2018 | 436 | 0.370 |
Why?
|
Cytogenetic Analysis | 11 | 2017 | 15 | 0.370 |
Why?
|
Age Factors | 15 | 2018 | 1105 | 0.370 |
Why?
|
Aminoglycosides | 3 | 2014 | 6 | 0.360 |
Why?
|
Hospitalization | 2 | 2018 | 417 | 0.360 |
Why?
|
Piperazines | 4 | 2011 | 56 | 0.360 |
Why?
|
Pyrimidines | 4 | 2011 | 60 | 0.350 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2018 | 83 | 0.350 |
Why?
|
Quality of Life | 2 | 2013 | 815 | 0.340 |
Why?
|
Acute Disease | 14 | 2013 | 239 | 0.330 |
Why?
|
Trans-Activators | 7 | 2011 | 47 | 0.330 |
Why?
|
Interleukin-2 | 4 | 2013 | 33 | 0.320 |
Why?
|
RNA, Neoplasm | 3 | 2014 | 20 | 0.320 |
Why?
|
DNA-Binding Proteins | 6 | 2016 | 142 | 0.310 |
Why?
|
DNA Mutational Analysis | 7 | 2017 | 67 | 0.310 |
Why?
|
Risk Factors | 13 | 2018 | 3509 | 0.300 |
Why?
|
Nuclear Proteins | 8 | 2019 | 71 | 0.300 |
Why?
|
Prospective Studies | 6 | 2016 | 2010 | 0.300 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2007 | 62 | 0.290 |
Why?
|
Comorbidity | 5 | 2018 | 539 | 0.280 |
Why?
|
Diphtheria Toxin | 5 | 2003 | 23 | 0.280 |
Why?
|
Neoplasms | 4 | 2019 | 608 | 0.280 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2016 | 13 | 0.270 |
Why?
|
Time Factors | 10 | 2015 | 1997 | 0.270 |
Why?
|
Antibodies, Monoclonal | 1 | 2007 | 196 | 0.270 |
Why?
|
Etoposide | 10 | 2013 | 30 | 0.260 |
Why?
|
Follow-Up Studies | 13 | 2019 | 2106 | 0.260 |
Why?
|
Mitochondria | 2 | 2018 | 174 | 0.250 |
Why?
|
DNA Methylation | 3 | 2014 | 129 | 0.250 |
Why?
|
Clinical Trials as Topic | 6 | 2017 | 298 | 0.240 |
Why?
|
Methotrexate | 4 | 2014 | 60 | 0.240 |
Why?
|
Oligonucleotide Array Sequence Analysis | 10 | 2013 | 155 | 0.240 |
Why?
|
Bone Marrow | 5 | 2018 | 60 | 0.230 |
Why?
|
DNA, Neoplasm | 4 | 2017 | 58 | 0.230 |
Why?
|
Salvage Therapy | 3 | 2015 | 118 | 0.230 |
Why?
|
Mitoxantrone | 4 | 2018 | 17 | 0.230 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 4 | 2012 | 6 | 0.230 |
Why?
|
Fusion Proteins, bcr-abl | 4 | 2011 | 8 | 0.230 |
Why?
|
Thalidomide | 2 | 2017 | 29 | 0.220 |
Why?
|
Multivariate Analysis | 6 | 2017 | 636 | 0.220 |
Why?
|
Lymphocytosis | 1 | 2002 | 1 | 0.220 |
Why?
|
Genetic Predisposition to Disease | 6 | 2018 | 836 | 0.220 |
Why?
|
Depression | 2 | 2016 | 378 | 0.210 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2016 | 16 | 0.210 |
Why?
|
Genes, Wilms Tumor | 3 | 2010 | 5 | 0.200 |
Why?
|
Cyclosporins | 4 | 2013 | 5 | 0.200 |
Why?
|
Cognition | 2 | 2016 | 524 | 0.190 |
Why?
|
Proportional Hazards Models | 9 | 2015 | 706 | 0.190 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2009 | 48 | 0.190 |
Why?
|
Genes, Neoplasm | 2 | 2017 | 18 | 0.190 |
Why?
|
Cohort Studies | 6 | 2017 | 1674 | 0.190 |
Why?
|
Recombinant Fusion Proteins | 5 | 2003 | 97 | 0.190 |
Why?
|
Cell Line | 2 | 2018 | 449 | 0.180 |
Why?
|
Burkitt Lymphoma | 2 | 2014 | 6 | 0.180 |
Why?
|
Retrospective Studies | 10 | 2018 | 3107 | 0.180 |
Why?
|
Tandem Repeat Sequences | 2 | 2012 | 5 | 0.180 |
Why?
|
Leukemia | 2 | 2014 | 36 | 0.180 |
Why?
|
Uniparental Disomy | 1 | 2019 | 1 | 0.180 |
Why?
|
Loss of Heterozygosity | 1 | 2019 | 17 | 0.180 |
Why?
|
Repressor Proteins | 3 | 2018 | 53 | 0.180 |
Why?
|
Chromosomes, Human | 1 | 2019 | 9 | 0.170 |
Why?
|
Goals | 1 | 2019 | 36 | 0.170 |
Why?
|
Predictive Value of Tests | 5 | 2013 | 784 | 0.170 |
Why?
|
Gene Expression | 3 | 2012 | 332 | 0.170 |
Why?
|
Chromosome Inversion | 3 | 2003 | 3 | 0.170 |
Why?
|
Neurofibromin 1 | 1 | 2018 | 1 | 0.170 |
Why?
|
Hyperglycemia | 1 | 2018 | 82 | 0.160 |
Why?
|
Cell Respiration | 1 | 2018 | 21 | 0.160 |
Why?
|
Communication | 1 | 2019 | 122 | 0.160 |
Why?
|
Retreatment | 1 | 2018 | 40 | 0.160 |
Why?
|
Genetic Loci | 1 | 2018 | 147 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2019 | 249 | 0.160 |
Why?
|
North Carolina | 2 | 2013 | 1422 | 0.160 |
Why?
|
Resuscitation Orders | 1 | 2017 | 11 | 0.160 |
Why?
|
Cytogenetics | 5 | 2019 | 6 | 0.160 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 4 | 2011 | 9 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 3 | 2014 | 90 | 0.160 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 169 | 0.160 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2017 | 3 | 0.160 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2017 | 4 | 0.160 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2017 | 11 | 0.150 |
Why?
|
Endothelial Growth Factors | 1 | 2017 | 12 | 0.150 |
Why?
|
Microsatellite Instability | 1 | 2017 | 1 | 0.150 |
Why?
|
Oxygen Consumption | 1 | 2018 | 138 | 0.150 |
Why?
|
Infusions, Intravenous | 2 | 2015 | 85 | 0.150 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.150 |
Why?
|
Trisomy | 2 | 2014 | 8 | 0.150 |
Why?
|
Immunologic Factors | 1 | 2017 | 48 | 0.150 |
Why?
|
Cyclin D1 | 1 | 2016 | 15 | 0.150 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2016 | 7 | 0.150 |
Why?
|
Cyclin D2 | 1 | 2016 | 7 | 0.150 |
Why?
|
Biopsy | 1 | 2018 | 241 | 0.150 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2011 | 37 | 0.150 |
Why?
|
Codon | 1 | 2016 | 7 | 0.150 |
Why?
|
Cardiovascular Abnormalities | 1 | 2016 | 1 | 0.150 |
Why?
|
WT1 Proteins | 3 | 2011 | 3 | 0.150 |
Why?
|
Subclavian Artery | 1 | 2016 | 6 | 0.150 |
Why?
|
Telomerase | 1 | 2016 | 21 | 0.150 |
Why?
|
Vascular Malformations | 1 | 2016 | 8 | 0.150 |
Why?
|
Intensive Care Units | 1 | 2017 | 118 | 0.150 |
Why?
|
Diverticulum | 1 | 2016 | 7 | 0.150 |
Why?
|
Aneurysm | 1 | 2016 | 21 | 0.140 |
Why?
|
Lung Neoplasms | 2 | 2017 | 384 | 0.140 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 189 | 0.140 |
Why?
|
Hemorrhage | 1 | 2017 | 90 | 0.140 |
Why?
|
Blood Glucose | 1 | 2018 | 465 | 0.140 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 680 | 0.140 |
Why?
|
Naphthyridines | 1 | 2015 | 5 | 0.140 |
Why?
|
Interferon-alpha | 3 | 2006 | 69 | 0.130 |
Why?
|
Polymorphism, Genetic | 1 | 2016 | 196 | 0.130 |
Why?
|
Thiazoles | 1 | 2015 | 32 | 0.130 |
Why?
|
Naphthalimides | 1 | 2015 | 1 | 0.130 |
Why?
|
Activities of Daily Living | 1 | 2016 | 237 | 0.130 |
Why?
|
Mice | 2 | 2018 | 2368 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2014 | 16 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 208 | 0.130 |
Why?
|
Chromosomes, Human, Pair 9 | 3 | 2004 | 13 | 0.130 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2017 | 179 | 0.130 |
Why?
|
Polypharmacy | 1 | 2014 | 20 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2015 | 337 | 0.120 |
Why?
|
Lymphoma | 1 | 2014 | 36 | 0.120 |
Why?
|
Defense Mechanisms | 1 | 2013 | 3 | 0.120 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 172 | 0.120 |
Why?
|
Sick Role | 1 | 2013 | 7 | 0.120 |
Why?
|
Personality Inventory | 1 | 2013 | 18 | 0.110 |
Why?
|
Affective Symptoms | 1 | 2013 | 16 | 0.110 |
Why?
|
Mood Disorders | 1 | 2013 | 19 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2011 | 262 | 0.110 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2013 | 100 | 0.110 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2017 | 15 | 0.110 |
Why?
|
Culture | 1 | 2013 | 38 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 248 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2013 | 59 | 0.110 |
Why?
|
Disease Progression | 4 | 2017 | 572 | 0.110 |
Why?
|
Animals | 5 | 2018 | 7297 | 0.110 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2012 | 7 | 0.110 |
Why?
|
Erythrocyte Transfusion | 2 | 2017 | 32 | 0.110 |
Why?
|
Asparaginase | 2 | 2015 | 5 | 0.110 |
Why?
|
Leukemia, B-Cell | 2 | 2002 | 4 | 0.110 |
Why?
|
Psychometrics | 1 | 2013 | 129 | 0.110 |
Why?
|
Recombinant Proteins | 4 | 2017 | 248 | 0.110 |
Why?
|
Logistic Models | 5 | 2015 | 725 | 0.110 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2009 | 5 | 0.110 |
Why?
|
Panax | 1 | 2012 | 8 | 0.110 |
Why?
|
Blast Crisis | 1 | 2011 | 1 | 0.110 |
Why?
|
Infant | 4 | 2018 | 967 | 0.110 |
Why?
|
Adaptation, Psychological | 1 | 2013 | 125 | 0.110 |
Why?
|
Patient Readmission | 1 | 2013 | 105 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 1079 | 0.100 |
Why?
|
Academic Medical Centers | 1 | 2013 | 150 | 0.100 |
Why?
|
Obesity | 2 | 2017 | 1062 | 0.100 |
Why?
|
Nursing Assessment | 1 | 2011 | 11 | 0.100 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 41 | 0.100 |
Why?
|
Child, Preschool | 4 | 2018 | 1164 | 0.100 |
Why?
|
Leukocyte Count | 3 | 2017 | 55 | 0.100 |
Why?
|
Neoplastic Stem Cells | 3 | 2017 | 90 | 0.100 |
Why?
|
Plant Extracts | 1 | 2012 | 60 | 0.100 |
Why?
|
Alleles | 3 | 2018 | 251 | 0.100 |
Why?
|
Up-Regulation | 4 | 2017 | 183 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2013 | 708 | 0.100 |
Why?
|
Gene Duplication | 1 | 2010 | 5 | 0.100 |
Why?
|
North America | 1 | 2010 | 33 | 0.100 |
Why?
|
Motor Activity | 1 | 2013 | 310 | 0.100 |
Why?
|
Stem Cells | 1 | 2013 | 292 | 0.090 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2010 | 6 | 0.090 |
Why?
|
Disability Evaluation | 1 | 2011 | 210 | 0.090 |
Why?
|
Child | 5 | 2018 | 2209 | 0.090 |
Why?
|
Risk Assessment | 6 | 2012 | 1300 | 0.090 |
Why?
|
Drug Resistance, Multiple | 3 | 2008 | 7 | 0.090 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 1 | 0.090 |
Why?
|
Benzamides | 4 | 2011 | 54 | 0.090 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2007 | 50 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 871 | 0.090 |
Why?
|
Histone-Lysine N-Methyltransferase | 4 | 2012 | 21 | 0.090 |
Why?
|
Polymerase Chain Reaction | 3 | 2017 | 172 | 0.090 |
Why?
|
Central Nervous System Neoplasms | 2 | 2012 | 28 | 0.090 |
Why?
|
Topotecan | 1 | 2009 | 15 | 0.090 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2009 | 38 | 0.080 |
Why?
|
Leukocytosis | 1 | 2008 | 8 | 0.080 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 1007 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 69 | 0.080 |
Why?
|
Genotype | 3 | 2018 | 735 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2009 | 37 | 0.080 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2007 | 1 | 0.080 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 22 | 0.080 |
Why?
|
Asparagine | 1 | 2007 | 6 | 0.080 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 138 | 0.070 |
Why?
|
Transplantation, Homologous | 3 | 2015 | 113 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2015 | 1374 | 0.070 |
Why?
|
Chromosome Deletion | 1 | 2006 | 9 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2007 | 65 | 0.070 |
Why?
|
Immunophenotyping | 2 | 2007 | 49 | 0.070 |
Why?
|
Antigens, CD | 1 | 2007 | 100 | 0.070 |
Why?
|
RNA, Messenger | 3 | 2017 | 514 | 0.070 |
Why?
|
Infant, Newborn | 2 | 2018 | 595 | 0.070 |
Why?
|
Phenotype | 3 | 2012 | 629 | 0.070 |
Why?
|
Splenomegaly | 1 | 2004 | 6 | 0.060 |
Why?
|
Anemia, Refractory | 1 | 2004 | 2 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2004 | 51 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2015 | 641 | 0.060 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2004 | 5 | 0.060 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2004 | 24 | 0.060 |
Why?
|
Fever of Unknown Origin | 1 | 2004 | 9 | 0.060 |
Why?
|
Vidarabine | 1 | 2003 | 3 | 0.060 |
Why?
|
Exanthema | 1 | 2004 | 21 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2017 | 855 | 0.060 |
Why?
|
Ergocalciferols | 1 | 2003 | 3 | 0.060 |
Why?
|
Combined Modality Therapy | 3 | 2012 | 524 | 0.060 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2002 | 3 | 0.060 |
Why?
|
Statistics, Nonparametric | 3 | 2008 | 129 | 0.060 |
Why?
|
Diabetes Insipidus, Neurogenic | 1 | 2002 | 1 | 0.060 |
Why?
|
Bacterial Toxins | 1 | 2002 | 16 | 0.060 |
Why?
|
Antigens, Bacterial | 1 | 2002 | 18 | 0.050 |
Why?
|
Monosomy | 1 | 2002 | 5 | 0.050 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2002 | 15 | 0.050 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2002 | 28 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2015 | 501 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2002 | 72 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 24 | 0.050 |
Why?
|
Chromosome Disorders | 1 | 2002 | 1 | 0.050 |
Why?
|
Anemia, Aplastic | 1 | 2002 | 6 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2002 | 69 | 0.050 |
Why?
|
Compassionate Use Trials | 2 | 2011 | 3 | 0.050 |
Why?
|
Bone Marrow Transplantation | 1 | 2002 | 65 | 0.050 |
Why?
|
Transplantation, Autologous | 2 | 2013 | 78 | 0.050 |
Why?
|
Survivors | 2 | 2016 | 145 | 0.050 |
Why?
|
Apoptosis | 1 | 2003 | 337 | 0.050 |
Why?
|
Cyclophosphamide | 3 | 2005 | 25 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2002 | 493 | 0.050 |
Why?
|
Gene Frequency | 2 | 2011 | 225 | 0.050 |
Why?
|
Administration, Oral | 2 | 2011 | 169 | 0.040 |
Why?
|
Comprehension | 1 | 2019 | 19 | 0.040 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2018 | 13 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2016 | 436 | 0.040 |
Why?
|
Disease Management | 1 | 2019 | 114 | 0.040 |
Why?
|
Health Personnel | 1 | 2019 | 111 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 273 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2017 | 16 | 0.040 |
Why?
|
Antibodies, Blocking | 1 | 2017 | 3 | 0.040 |
Why?
|
Angiogenic Proteins | 1 | 2017 | 9 | 0.040 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
Clone Cells | 1 | 2017 | 36 | 0.040 |
Why?
|
Genes, p53 | 1 | 2017 | 23 | 0.040 |
Why?
|
Genes, ras | 1 | 2017 | 26 | 0.040 |
Why?
|
Decision Making | 1 | 2019 | 180 | 0.040 |
Why?
|
Patient Transfer | 1 | 2017 | 34 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 77 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 542 | 0.040 |
Why?
|
Physical Examination | 1 | 2016 | 82 | 0.040 |
Why?
|
Proteins | 1 | 2017 | 140 | 0.030 |
Why?
|
Body Surface Area | 1 | 2015 | 14 | 0.030 |
Why?
|
RNA | 1 | 2016 | 88 | 0.030 |
Why?
|
Genetic Markers | 2 | 2008 | 122 | 0.030 |
Why?
|
Mental Health | 1 | 2016 | 102 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2018 | 360 | 0.030 |
Why?
|
Aziridines | 2 | 2005 | 3 | 0.030 |
Why?
|
Benzoquinones | 2 | 2005 | 5 | 0.030 |
Why?
|
Patient Discharge | 1 | 2016 | 168 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 2 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 6 | 0.030 |
Why?
|
Mobility Limitation | 1 | 2016 | 187 | 0.030 |
Why?
|
Transcription Factors | 1 | 2016 | 172 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 13 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 26 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2014 | 19 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2017 | 573 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 48 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2014 | 54 | 0.030 |
Why?
|
Platelet Count | 1 | 2014 | 21 | 0.030 |
Why?
|
Filgrastim | 1 | 2014 | 4 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 21 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2013 | 3 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 11 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2013 | 10 | 0.030 |
Why?
|
Dogs | 1 | 2014 | 117 | 0.030 |
Why?
|
Smoking | 1 | 2017 | 427 | 0.030 |
Why?
|
DNA Damage | 1 | 2013 | 88 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2013 | 97 | 0.030 |
Why?
|
United States | 2 | 2012 | 3604 | 0.030 |
Why?
|
Risk | 1 | 2014 | 289 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 2 | 2003 | 12 | 0.030 |
Why?
|
Boronic Acids | 1 | 2012 | 7 | 0.030 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 5 | 0.030 |
Why?
|
Peripheral Nervous System | 1 | 2012 | 6 | 0.030 |
Why?
|
Pyrazines | 1 | 2012 | 11 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 10 | 0.030 |
Why?
|
Cell Division | 2 | 2003 | 97 | 0.030 |
Why?
|
Drug Synergism | 1 | 2012 | 67 | 0.030 |
Why?
|
European Continental Ancestry Group | 1 | 2017 | 1131 | 0.030 |
Why?
|
F-Box Proteins | 1 | 2012 | 4 | 0.030 |
Why?
|
Injections, Subcutaneous | 2 | 2002 | 33 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2012 | 9 | 0.030 |
Why?
|
Body Mass Index | 1 | 2015 | 862 | 0.030 |
Why?
|
Bone Marrow Cells | 2 | 2003 | 114 | 0.030 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 2011 | 1 | 0.030 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 17 | 0.030 |
Why?
|
Exons | 1 | 2011 | 49 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 199 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2013 | 863 | 0.020 |
Why?
|
African Americans | 1 | 2017 | 1373 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 83 | 0.020 |
Why?
|
Homeostasis | 1 | 2010 | 127 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 49 | 0.020 |
Why?
|
Ideal Body Weight | 1 | 2009 | 7 | 0.020 |
Why?
|
Diarrhea | 1 | 2009 | 56 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 284 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2009 | 10 | 0.020 |
Why?
|
Fatigue | 1 | 2009 | 68 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2009 | 54 | 0.020 |
Why?
|
Busulfan | 1 | 2008 | 4 | 0.020 |
Why?
|
Incidence | 1 | 2012 | 1105 | 0.020 |
Why?
|
RNA Probes | 1 | 2008 | 4 | 0.020 |
Why?
|
Isoleucine | 1 | 2007 | 8 | 0.020 |
Why?
|
Aspartic Acid | 1 | 2007 | 13 | 0.020 |
Why?
|
Immunotherapy | 1 | 2008 | 69 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2008 | 454 | 0.020 |
Why?
|
Expressed Sequence Tags | 1 | 2005 | 2 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2007 | 203 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2004 | 17 | 0.020 |
Why?
|
Tomography, Emission-Computed | 1 | 2003 | 25 | 0.010 |
Why?
|
U937 Cells | 1 | 2003 | 8 | 0.010 |
Why?
|
HL-60 Cells | 1 | 2003 | 14 | 0.010 |
Why?
|
Blotting, Southern | 1 | 2003 | 21 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2003 | 74 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 2003 | 11 | 0.010 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2002 | 6 | 0.010 |
Why?
|
Cell Cycle | 1 | 2003 | 69 | 0.010 |
Why?
|
Bacillus anthracis | 1 | 2002 | 9 | 0.010 |
Why?
|
Thymidine | 1 | 2002 | 7 | 0.010 |
Why?
|
Partial Thromboplastin Time | 1 | 2002 | 6 | 0.010 |
Why?
|
Hypocalcemia | 1 | 2002 | 8 | 0.010 |
Why?
|
Aging | 1 | 2009 | 880 | 0.010 |
Why?
|
Binding Sites | 1 | 2002 | 125 | 0.010 |
Why?
|
Blood Cell Count | 1 | 2002 | 26 | 0.010 |
Why?
|
Liver Failure | 1 | 2002 | 17 | 0.010 |
Why?
|
Aspartate Aminotransferases | 1 | 2002 | 28 | 0.010 |
Why?
|
Alanine Transaminase | 1 | 2002 | 44 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2002 | 93 | 0.010 |
Why?
|
Models, Molecular | 1 | 2002 | 178 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 158 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 280 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 2002 | 53 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 350 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2002 | 92 | 0.010 |
Why?
|
Treatment Failure | 1 | 2002 | 159 | 0.010 |
Why?
|
Pilot Projects | 1 | 2003 | 469 | 0.010 |
Why?
|
Cytokines | 1 | 2002 | 243 | 0.010 |
Why?
|